一线PD-1/VEGF双特异性抗体联合化疗治疗三阴性乳腺癌的2期试验
这项开放标签、多中心、单臂2期试验评估了依沃西单抗联合化疗作为局部晚期不可切除或转移性三阴性乳腺癌一线治疗的安全性和疗效。共入组36例患者,中位随访22.1个月,主要终点达到;客观缓解率为80.0%(95%CI 63.1-91.6),≥3级治疗相关不良事件发生率为58.3%。
要点
- 依沃西单抗联合化疗一线治疗晚期三阴性乳腺癌客观缓解率达80.0%。
- ≥3级治疗相关不良事件发生率为58.3%,未发生治疗相关死亡。
- 免疫相关不良事件发生率为41.7%,≥3级为11.1%。
核心结论
- 依沃西单抗联合化疗作为既往未治疗晚期三阴性乳腺癌一线治疗显示出鼓舞人心的抗肿瘤活性,值得进一步研究。
研究设计与样本
- 开放标签、多中心、单臂2期临床试验,入组36例既往未接受系统治疗的局部晚期不可切除或转移性三阴性乳腺癌女性患者。
- 患者接受依沃西单抗20 mg kg-1静脉注射每2周一次,联合紫杉醇90 mg m-2或白蛋白结合型紫杉醇100 mg m-2,每4周周期第1、8、15天静脉给药。
- 主要终点为安全性和研究者根据RECIST v1.1评估的客观缓解率。
主要发现
- 截至2025年7月15日,中位随访时间为22.1个月,主要终点达到。
- 36例(100.0%)患者发生治疗相关不良事件,21例(58.3%)发生≥3级治疗相关不良事件,未发生治疗相关死亡。
- 15例(41.7%)患者发生免疫相关不良事件,其中4例(11.1%)为≥3级。
- 35例可评估疗效患者中,客观缓解率为80.0%(95%置信区间:63.1-91.6),包括2例(5.7%)完全缓解和26例(74.3%)部分缓解。
临床怎么用
- 该联合方案可作为既往未治疗晚期三阴性乳腺癌的潜在一线治疗选择,但需进一步研究验证。
局限性
- 本研究为单臂2期试验,样本量较小(36例),无对照组,结论需随机对照试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Triple-negative breast cancer is an aggressive subtype comprising 10-20% of all breast cancer cases and has a worse prognosis than other subtypes. This open-label, multicenter, single-arm, phase 2 clinical trial evaluates the safety and efficacy of ivonescimab combined with chemotherapy as first-line treatment in female patients with locally advanced unresectable or metastatic triple-negative breast cancer who have not received previous systemic therapy. Eligible patients received ivonescimab 20 mg kg-1 intravenously every 2 weeks and paclitaxel 90 mg m-2 or nab-paclitaxel 100 mg m-2 intravenously on days 1, 8 and 15 of each 4-week treatment cycle. The primary endpoints were safety and the investigator-assessed objective response rate per RECIST v.1.1. A total of 36 patients were enrolled. As of July 15, 2025, the median follow-up duration was 22.1 months. The primary endpoints were met. Treatment-related adverse events occurred in 36 (100.0%) patients. Grade ≥3 treatment-related adverse events were reported in 21 (58.3%) patients. No treatment-related deaths occurred. Immune-related adverse events occurred in 15 (41.7%) patients, with grade ≥3 events in 4 (11.1%) patients. Of the 35 patients evaluable for treatment efficacy, the objective response rate was 80.0% (95% confidence interval: 63.1-91.6), including 2 (5.7%) complete responses and 26 (74.3%) partial responses. Ivonescimab plus chemotherapy demonstrated encouraging antitumor activity as first-line therapy for patients with previously untreated advanced triple-negative breast cancer and merits further investigation. ClinicalTrials.gov identifier: NCT05227664 .
引用
- Shao X, Tian C, Chen Z, et al. First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial. Nat Med. 2026. PMID: 42587052. doi:10.1038/s41591-026-04564-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。